Abstract
The outlook for patients with psoriasis has improved significantly over the last 10 years with the introduction of targeted therapies. Cytokines exert their effects by activating intracellular signaling and transcription pathways, among which there are Janus kinases (JAKs) and signal transducers and activators of transcription (STAT) pathways. JAKs are intracellular second messengers that are crucial for transmitting extracellular cytokine signals to the cell. JAK inhibition interrupts intracellular signaling and can suppress immune cell activation and inflammation in T-cell-mediated disorders, such as psoriasis. Consequently, JAKs are the subject of intensive research activity, since they represent possible therapeutic targets. Tofacitinib is an orally available compound belonging to a novel category of nonbiologic drugs, the "JAK inhibitors", which target JAKs. Recently, oral and topical formulations of tofacitinib have been demonstrated to be safe and effective for the treatment of plaque psoriasis in randomized clinical trials. In particular, a 10 mg bid dose of tofacitinib was shown to be noninferior to etanercept 50 mg subcutaneously twice weekly. Questions remain unresolved regarding the safety risk beyond the 5 mg bid d...Continue Reading
Citations
Jun 9, 2016·Expert Opinion on Pharmacotherapy·M GalluzzoM Talamonti
Jan 7, 2017·Allergology International : Official Journal of the Japanese Society of Allergology·Masutaka FurueTakafumi Kadono
Feb 1, 2017·Journal of the American Academy of Dermatology·William Damsky, Brett A King
Dec 27, 2016·The Journal of Dermatological Treatment·Aniseh SamadiAlireza Firooz
Jan 11, 2018·International Journal of Molecular Sciences·Enzo CalauttiValeria Poli
Aug 7, 2019·Experimental Dermatology·Fei YiXiangsheng Chen
May 3, 2019·Pediatric Rheumatology Online Journal·M BoyadzhievS Hambleton
Nov 12, 2017·Archives of Dermatological Research·Hanan Rabea NadaSally Mamdouh
Dec 26, 2018·Journal of Immunology Research·Martina MorelliCristina Albanesi
Mar 10, 2017·Expert Review of Clinical Pharmacology·Ramya Vangipuram, Ali Alikhan
Nov 3, 2017·Clinical Drug Investigation·Alexandra Azevedo, Tiago Torres
May 16, 2021·Experimental & Molecular Medicine·Lihua HaoByung-Hyun Park
Jul 19, 2019·Journal of Medicinal Chemistry·Stephen T WrobleskiDavid S Weinstein
Aug 8, 2021·British Journal of Pharmacology·Lihua HaoByung-Hyun Park